key: cord-0802656-jk2xnkcb authors: Uzuncakmak, Tugba Kevser; Özkoca, Defne; Askin, Ozge; Kutlubay, Zekayi title: Can rituximab be used in the treatment of pemphigus vulgaris during the COVID‐19 pandemic? date: 2020-12-15 journal: Dermatol Ther DOI: 10.1111/dth.14647 sha: 4362ae53b9b64205ff3fe8b3671d5b78229c7ba7 doc_id: 802656 cord_uid: jk2xnkcb Rituximab is a monoclonal antibody that targets CD20, a B‐lymphocyte antigen; that leads to a decline in the B‐cell counts for at least a year. The patients who have received rituximab treatment in the previous 5 years with the diagnosis of pemphigus group of diseases at Cerrahpaşa Medical Faculty were questioned for COVID‐19 infection. A total of 48 patients were included in this study; only one male patient had COVID‐19 infection which had a mild course. There is no significant difference in the total number of lymphocytes between patients who have received rituximab within the previous 5 years or last year. The number of lymphocytes is independent of the number of courses of rituximab treatment received. Therefore, we suggest that all pemphigus patients who have received rituximab treatment within the previous 5 years should be careful of the preventive measures against the COVID‐19 infection irrespective of the number of treatment courses or the number of years which has passed since the treatment. The disease course was mild in the only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID‐19 pandemic if its use is necessary. COVID-19 infection, he was questioned about the course of the disease. The approval of the Cerrahpaşa Medical Faculty Ethics Commitee was taken before initiating the study. Statistical analysis was done using SPSS 21. Descriptive analysis was analyzed with average, SD, median, and quarantiles (25-75). Continuous variables were analyzed with the Shapiro Wilk test. The relationship between the lymphocyte count and the total number of treatment courses was analyzed with Kruskal-Wallis test. The patients who have received a single treatment course are compared to those who have received multiple courses in terms of lymphocyte count using the Mann-Whitney U test. A P value below .05 was considered as significant. A total of 48 patients were included in this study. Fourteen patients (29.2%) were male and 34 patients (%70.8) were female. The mean age of all patients was 45.58 ± 12.1 years. The mean age of male patients was 41.5 ± 11.2 years and the mean age of female patients was 47.2 ± 12.3 years. Thirty-five patients (72.9%) received a single course of treatment; nine patients (18.8%) received two courses, three patients (6.3%) received three courses and one patient (2.1%) received four courses. Only one patient had been diagnosed with COVID-19 infection; who has received a single treatment course and has a lymphocyte count of 1.2 × 10 3 /μl. The mean lymphocyte count of all patients was 1.92 ± 0.81 × 10 3 /μl. There is no significant relationship between the total number of treatment courses received and the lymphocyte count (P = .086). Furthermore, no significant relationship was found between the number of treatment courses received and the lymphocyte counts (P = .084). Of all the patients, 17 (35.4%) received rituximab treatment within the last year. Two of the patients (4%) were diagnosed as pemphigus foliaceus and 46 (96%) patients had pemphigus vulgaris. The mean lymphocyte count of the patients who has received the treatment within the previous year was 175.8 ± 0.92 × 10 3 /μl. The mean lymphocyte count of other patients was 2.02 ± 0.75 × 10 3 /μl. There is no significant difference between the lymphocyte counts of these two groups (P = .206; Table 1 ). The COVID-19 disease has emerged in China in December 2019; and it soon has evolved into a pandemic. 5 Decreased lymphocyte counts were found to lead to a severe course of COVID-19. 6 Rituximab decreases the B-cell counts and the overall lymphocyte counts. The patients receiving rituximab treatment are more prone to viral infections than the normal population. 1 Previously, it was reported that rituximab use increased the hospitalization rate, made the prognosis of the disease worse, and increased the mortality rate in patients with a group of rheumatologic diseases. The disease-specific mortality rate in patients receiving rituximab was 37.5%. On the other hand, the mortality rate of the COVID-19 was calculated as 28% in a multicenter study. Thus, rituximab use has the potential of leading to an unfavorable disease course or outcome in patients during the COVID-19 pandemic. 7 Pemphigus vulgaris is a potentially mortal disease without treatment; the use of immunomodulatory drugs including rituximab had a pivotal role in decreasing the mortality rate of pemphigus vulgaris. 9 Immunomodulatory drugs increase the rate of viral infections and it is important to note that infections could lead to relapses of pemphigus vulgaris. 10 It is known that the combination therapy of short term sys- There are three review articles regarding the management of pemphigus vulgaris patients during the COVID-19 pandemic. All of the authors agree that rituximab use should be postponed during the pandemic. [14] [15] [16] Since infections can also lead to disease relapses 10 in alignment with our results, we suggest that rituximab therapy could be given during the pandemic if the benefit outweighs the risk, as in our patient's case. In conclusion, rituximab treatment has the potential of worsening However, COVID-19 had a mild course in our only infected patient. Thus, rituximab may be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic if its use is absolutely necessary. Efficacy of repeated courses of rituximab as treatment for pemphigus vulgaris Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: a narrative review Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial Prolonged incubation of SARS-CoV-2 in a patient on rituximab therapy COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a telemedicine experience Treatment considerations for patients with pemphigus during the COVID-19 pandemic Management of pemphigus in COVID-19 pandemic era; a review article How to cite this article: Uzuncakmak TK, Özkoca D, Askin O, Kutlubay Z. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?